Skip to main content Skip to search Skip to main navigation

EC: New ways to conduct Notified Body-audits during COVID-19

On 8 April 2020, the Medical Device Coordination Group (MDCG) published a five-page guideline on the conduct of audits by Notified Bodies to be applied during the COVID 19 pandemic. 

Under certain circumstances, remote audits should now also be possible. The guideline will be effective immediately and will be valid for the duration of the COVID 19 pandemic according to the classification by the World Health Organisation (WHO).

The following audits for conformity assessments of medical devices are covered by the guideline:

  • Surveillance audits under the medical devices Directives,
  • Audits conducted for re-certification purposes under the medical devices Directives,
  • In cases where a manufacturer submits a change notification to a notified body that would typically require on-site audit or verification,
  • In cases where a manufacturer terminates (voluntarily or involuntarily) its contract with a notified body and enters into a contract with another notified body in respect of the conformity assessment of the same device(s).

The following temporary extraordinary measures and arrangements may be conducted as an alternative to on-site audits:

  • Postponement of on-site surveillance audits under the Directives in line with documented procedures of the notified body for force majeure.
  • On-site audits may be replaced by remote audits using the most advanced available Information and Communication Technologies as appropriate in accordance with legislation on information security and data protection.
  • Assessment of all relevant and required documents/records off-site by the notified body.
  • To take into account existing recent results from MDSAP audits (or other appropriate audits) in lieu of Directive audits, where available
  • To consider published international guidance such as those issued by the International Accreditation Forum (IAF) e.g. on how to use information and communication technologies and for alternative auditing methods in extraordinary circumstances

New approaches will be followed during the pandemic here as well. It needs to be shown to what extent modern communication technologies for conducting audits continue to be possible in the future.


Source:

EC: Guidance on temporary extraordinary measures related to medical device Notified Body audits during COVID-19 quarantine orders and travel restrictions

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next